Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Trane Technologies plc (TT) Price & Performance

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)Trade
Trane Technologies plcTrade

Price performance (Past 24H)

Key statistics

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Trane Technologies plc — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $19.3 (market cap $60.06B), while Trane Technologies plc trades at $471.29 (market cap $105.17B). The key difference: Trane Technologies plc is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals.

TAKTT
Market Cap
$60.06B$105.17B
Volume
2,925,0421,040,183
Sector
HealthIndustrials
52-Week High
$19.05$503.46
52-Week Low
$13.23$376.43
Typical Hold Time
6 Days—
Enterprise Value
$87.89B$108.47B
Dividend Yield
3.33%0.88%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

TAK trades at $18.52, down 0.86% on the day. The stock shows mixed signals with a bullish technical outlook from moving averages but neutral oscillators. Recent financials reveal a net income margin of -3.54% for 2026, though revenue remains stable near $4.6 trillion. Positive developments include the launch of ORZEYFUL for narcolepsy and FDA priority review for zasocitinib, highlighting a robust pipeline. Cash flow improved to $209.8 billion in 2026 from a negative position in 2025.

Outlook: TAK's strong analyst support (83% buy ratings) and promising drug pipeline offer growth potential, but profitability concerns and high P/E of 51.56 pose risks. Investors should weigh pipeline successes against current negative margins and elevated valuation.

Trane Technologies plc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.

Read more on TAK →

About Trane Technologies plc

Trane Technologies plc is a global climate solutions company that designs, manufactures, and services heating, ventilation, and air conditioning (HVAC) and transport refrigeration equipment under its Trane and Thermo King brands.

Read more on TT →